Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

Abstract Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA). Treatment with the direct oral thrombin inhibitor dabigatran appears to be associated with a r...

Full description

Bibliographic Details
Main Authors: Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
dabigatran
factor Xa inhibitors
menorrhagia
prospective studies
tranexamic acid
Online Access:https://doi.org/10.1002/rth2.12471

Similar Items

Similar Items